This commentary proposes a hybrid drug pricing reform model balancing most favored nation (MFN) benchmarking with domestic negotiation strategies that drive equity-focused valuation frameworks.
Franklyn Rocha Cabrero, MD
Advertisement
Articles by Franklyn Rocha Cabrero, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Real-World Data Show Most CRS, ICANS Cases Happen Within 15 Days of Liso-Cel Infusion
2
From Trial Diversity to Telehealth: Advancing Equity and Access in Rural and Underserved Cancer Care
3
Long-Term Adalimumab Improves Work, Life Quality in Psoriasis
4
Real-World Usage of Nintedanib for PPF Differs From Trial Settings
5
